Scale-Up and Scale-Down in Biopharma with Process Analytical Technology (PAT)

How to Use Real-Time Analytics to De-Risk Your Full-Scale Biomanufacturing

Optimizing Scale-up and Scale-down in Biopharma is essential for transitioning successfully from benchtop experiments to full-scale commercial production

Scaling a bioprocess from a benchtop vessel to the factory floor is rarely a linear journey. While a monoclonal antibody (mAb) expression might thrive in a 15 L glass bioreactor, the transition to industrial volumes introduces physical stresses (mixing lags, k_La fluctuations, and thermal gradients) that can jeopardize years of development. Scaling up to 20,000 L working volumes is more than a hardware upgrade; it's a data challenge.

Process Analytical Technology (PAT) provides the unified framework to meet it, keeping scale-up parameters and scale-down models synchronized to maintain process control at every stage—and ensuring a reliable, right-first-time transition from bench to production.

Scale-up is critical because it translates a biologically proven, optimized small-scale process into a reliable, efficient industrial-scale operation capable of handling thousands of liters of culture volume.

Scale-up plays a key role for several reasons:

Only industrial-scale biomanufacturing can produce biotherapeutics (like monoclonal antibodies) in the volumes necessary to make them economically viable and accessible to patients globally.

It transforms promising lab discoveries into a consistent, repeatable manufacturing process required for regulatory approval.

It directly addresses the unique engineering challenges that only emerge at large volumes, such as heterogeneity, oxygen transfer limitations measured by k_La and critical process parameter descrepencies.

Scale-up is the ultimate test of whether your cell line, media, and process conditions will thrive under industrial realities. It’s the make-or-break step in delivering therapies to patients at scale.
Ehsan Mahdinia, Industry Manager for Pharma and Biotechnology

While both are integral to biomanufacturing, it’s important to clearly distinguish seed train from scale-up:

Aspect	Seed Train	Scale-Up
Primary Goal	Routine expansion of cell biomass	One-time, rigorous process to reach industrial production scale
Complexity	Low to moderate: follows established protocols	High: involves significant unknowns and complex engineering translation
Monitoring	Minimal: based on established protocols	Intensive use of PAT for detailed characterization and control
Risk Profile	Low: repeated thousands of times routinely	High: failure is costly and profoundly impacts the product pipeline

The seed train uses established protocols to routinely multiply cell culture batches. In contrast, scale-up requires rigorous experimentation and characterization to ensure that the process parameters translate reliably and to prevent catastrophic failures at the production scale.

The scale-up journey involves distinct stages, each serving a unique scientific and operational purpose:

Scale	Working Volume	Typical Biopharma Use Case
Micro-Scale	< 500 mL	Clone selection, high-throughput media screening, early process development
Benchtop-Scale	0.5 L – 15 L	Growth parameter optimization, early proof-of-concept (POC) studies
Pilot-Scale	15 L – 500 L	Scalability verification, process refinement, generating clinical material
Production-Scale	> 1000 L	Full-scale commercial biomanufacturing with optimized control

Scale Up Scale Down in Biopharma - on-demand webinar

Pilot-Scale: The Bridge for Scalability Verification

Pilot-scale bioreactors are the experimental proving ground. They operate at a volume large enough to effectively mimic industrial conditions, allowing you to test scaling parameters such as mixing, oxygen transfer, and nutrient feeding, without the prohibitive financial and operational risks associated with a full production run.

Watch the on-demand webinar, in which we explore the critical role PAT plays in scale-up scale-down in biopharma operations.

Watch it now!

Pilot-scale is where the crucial question of scalability is answered. You collect the data, tweak the parameters, and then hand over the blueprint to MSAT (Manufacturing Sciences and Technology) teams who decide the fate of production.
Ehsan Mahdinia, Industry Manager for Pharma and Biotechnology

Solving Mixing Heterogeneity and Mass Transfer Limitations at Scale

The greatest technical hurdle in large-scale bioreactors is maintaining a consistent, homogeneous environment. As volume increases, mixing becomes challenging due to:

Increased Mixing Times leading to heterogeneous dead zones

Viscosity Changes affecting overall fluid dynamics and shear stress

Oxygen Transfer Limitations impacting critical aerobic cell metabolism

Good mixing ensures the even distribution of nutrients, gases (especially oxygen), temperature, and pH. Poor mixing leads to zones where cells suffer from oxygen or nutrient deprivation, which causes batch inconsistency and catastrophic results in biomanufacturing.

For aerobic bioprocesses (like those using CHO cells to produce mAbs), oxygen is the limiting nutrient. If oxygen supply fails, the cells stop producing or die.

The Volumetric Oxygen Transfer Coefficient is the definitive metric for measuring oxygen transfer efficiency from the gas phase to the liquid phase.

Accurate k_La measurement is complex, empirical, and must be performed and characterized at every scale to ensure predictability.
Innovations like dissolved oxygen (DO) sensors with anti-bubble, noise reduction properties significantly improve accuracy - a necessity for large tanks.

Without oxygen, you face cell energy bankruptcy. The cells die or stop producing. This parameter dominates scale-up strategy more than mixing time or shear stress in biopharma.
Ehsan Mahdinia, Industry Manager for Pharma and Biotechnology

Effective scale-up demands real-time monitoring and control of all Critical Process Parameters (CPPs) that decide Critical Quality Attributes (CQAs).

PAT provides the necessary tools for this control:

Critical Parameter	Importance	Challenges at Large Scale	PAT Solution
pH	Crucial for cell viability and product integrity	Dead zones can cause localized pH deviation and subsequent cell death	High-accuracy in-line pH sensors and multiple sampling points
ORP	High levels can cause oxidative stress on cells. Low levels result in product degradation	Impacts final product quality	Real-time in-line ORP monitoring for proactive control
CO₂Concentration	Affects cell metabolism and product efficacy	Accumulation in large, deep fermenters due to hydrostatic pressure	In-line CO₂sensors and essential off-gas analyses

The Value of Consistent, Synchronized PAT Across Scales

Integrating PAT tools uniformly from micro-scale through production creates a unified digital framework that dramatically improves process performance:

Data Comparability

Enables faster root cause analyses and troubleshooting when deviations occur.

Seamless Tech Transfer

Reduces the incidence of seed train failures and gaps during technology transfer.

Compliance

Provides unified digital audit trails for robust regulatory submission.

The industry is also increasingly adopting single-use sensors to simplify cleaning validation, reduce cross-contamination risk, and facilitate precise scale-down studies.

You cannot control what you cannot model, and you cannot model what you cannot monitor. PAT is our eyes and ears throughout the scale-up journey.
Ehsan Mahdinia, Industry Manager for Pharma and Biotechnology

Scale-down involves replicating large-scale production conditions in smaller, more manageable systems such as benchtop fermenters. This approach is critical for process development, optimization, troubleshooting, and ensuring consistency across scales before and after moving to full-scale production.

A key aspect of effective scale-down is the use of consistent sensor technology across all scales—from R&D to pilot plants to full production. Utilizing the same pH and dissolved oxygen (DO) sensors equipped with Intelligent Sensor Management (ISM) technology offers numerous advantages. ISM sensors provide advanced diagnostics, plug-and-measure capabilities, and compliance with stringent regulatory standards. This uniformity simplifies calibration procedures, streamlines supply chains, and ensures high data quality and reliability.

Accurate calibration underpins effective scale-down processes. Sensors undergo precise two-point calibration (zero gas and compensated air point for DO sensors for instance) before use to establish a reliable baseline. Post-sterilization, sensors may experience slight deviations (offset) due to factors like overpressure and sterile filter backpressure. To maintain calibration fit and sensor accuracy, process scaling methods adjust sensor readings to desired values rather than recalibrating, thus compensating for offsets without compromising performance.

Maintaining similar process parameters and sensor technology across scales ensures smooth technology transfer, reduces variability, and enhances process robustness.

ISM-enabled predictive diagnostics further support this by facilitating timely maintenance and calibration, reducing downtime, and preventing disruptions during critical manufacturing batches.

Integrating accurate, digital, and reliable Process Analytical Technology (PAT) in scale-down strategies enables real-time monitoring and control of critical quality attributes and process parameters. This data-driven approach improves process control, product quality, and regulatory compliance, while reducing operational costs and risks via enabling smoother root-cause analyses.

Key Takeaways for Successful Biomanufacturing Scale-Up and Scale-Down

Holistic Control Is Essential

Recognize that both scale-up and scale-down are multi-step processes that demand comprehensive and simultaneous management of biological, chemical, and engineering variables to ensure process robustness and product quality.

kLa Remains a Priority

Oxygen transfer measurement and control are critical, especially during scale-up, to maintain optimal cell growth and productivity.

Unified PAT Solutions

Implement consistent and synchronized Process Analytical Technology (PAT) across all scales—from R&D to pilot to production—to facilitate smooth technology transfer, reliable monitoring, and efficient troubleshooting.

Ensure Calibration Consistency

Apply precise and standardized calibration and process scaling methods to maintain sensor accuracy and data integrity across scales, supporting reliable decision-making and regulatory compliance.

Embrace Digital and Regulatory Compliance

Utilize digital PAT tools that provide data integrity, remote monitoring, and compliance with regulatory standards to enhance efficiency and quality throughout the biomanufacturing lifecycle.

Successful biopharmaceutical manufacturing hinges on the seamless integration of scale-up and scale-down models supported by robust PAT. Maintaining consistent instrumentation and real-time data flow across scales ensures a "right-first-time" transition from bench to plant. By de-risking production and accelerating process development, these strategies provide a direct path to the economical and compliant manufacturing of life-saving biologics.

Learn More